Patents by Inventor Paul J. Hergenrother
Paul J. Hergenrother has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200190029Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.Type: ApplicationFiled: February 26, 2020Publication date: June 18, 2020Applicant: The Board of Trustees of the University of IllinoisInventors: David J. SHAPIRO, Paul J. Hergenrother, Matthew W. Boudreau
-
Publication number: 20200123173Abstract: Inhibitors of human topoisomerase II (Top2) are the backbone of numerous cancer chemotherapy regimens. Unfortunately, the onset of toxicity severely limits the utility of these powerful drugs. There is some conservation between human Top2 and bacterial homologues (DNA gyrase and TopoIV). Thus, the conversion of antibacterial topoisomerase inhibitors into antineoplastic agents is an intriguing strategy for anticancer compounds. Herein is described the conversion of deoxynybomycin (DNM), a natural product and DNA gyrase inhibitor with minimal cytotoxicity, into a compound that has anticancer activity. Detailed in vitro and cell culture experiments demonstrate that these compounds inhibit Top2 and also act upon topoisomerase I. Similar approaches are applicable to other classes of gyrase inhibitors and other antibacterial targets for discovery of new anticancer drugs.Type: ApplicationFiled: June 21, 2018Publication date: April 23, 2020Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Paul J. HERGENROTHER, Andrew P. RILEY
-
Patent number: 10576096Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.Type: GrantFiled: December 6, 2017Date of Patent: March 3, 2020Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
-
Patent number: 10525056Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.Type: GrantFiled: July 17, 2018Date of Patent: January 7, 2020Assignee: The Board of Trustees of the University of IllinoisInventor: Paul J. Hergenrother
-
Publication number: 20190358229Abstract: Compositions and methods for the induction of cancer cell death. The compositions and methods of using them include use of compositions in therapy for the treatment of cancer and for the selective induction of apoptosis in cancer cells. The drug combinations described herein can be synergistic and can have lower neurotoxicity effects than the same amounts of other compounds and combinations of compounds and can be effective when a particular cancer has become resistant to previously administered therapies.Type: ApplicationFiled: June 10, 2019Publication date: November 28, 2019Applicant: The Board of Trustees of the University of IllinoisInventors: Paul J. HERGENROTHER, Jessie PEH
-
Patent number: 10350207Abstract: The invention provides compositions and methods for the induction of cancer cell death. The compositions and methods of using them include use of compositions in therapy for the treatment of cancer and for the selective induction of apoptosis in cancer cells. The drug combinations described herein can be synergistic and can have lower neurotoxicity effects than the same amounts of other compounds and combinations of compounds, and can be effective when a particular cancer has become resistant to previously administered therapies.Type: GrantFiled: June 6, 2016Date of Patent: July 16, 2019Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Jessie Peh
-
Publication number: 20190201394Abstract: Compositions and methods relating to induction of cell death such as in cancer cells are disclosed. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds in connection with modification of procaspases such as procaspase-3 are disclosed. In various embodiments, the compounds and compositions are capable of activation of procaspase-3.Type: ApplicationFiled: December 21, 2018Publication date: July 4, 2019Applicant: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Karson S. Putt, Quinn P. Peterson, Valerie Fako
-
Publication number: 20190152891Abstract: The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.Type: ApplicationFiled: September 20, 2018Publication date: May 23, 2019Applicant: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Robert W. Huigens, III, Karen C. Morrison, Robert W. Hicklin, II, Timothy A. Flood
-
Patent number: 10285986Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: GrantFiled: March 23, 2018Date of Patent: May 14, 2019Assignees: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Publication number: 20190135821Abstract: Disclosed are compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.Type: ApplicationFiled: March 13, 2017Publication date: May 9, 2019Inventors: Paul J. HERGENROTHER, Michelle Richter, Andrew Riley, Bryon Drown, Martin Chavez, Sarah Tasker, Alfredo Garcia
-
Patent number: 10272099Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.Type: GrantFiled: April 8, 2014Date of Patent: April 30, 2019Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois.Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
-
Publication number: 20190099418Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: October 1, 2018Publication date: April 4, 2019Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Howard S. ROTH, Theodore M. TARASOW
-
Publication number: 20190099419Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: October 1, 2018Publication date: April 4, 2019Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins UniversityInventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Avadhut JOSHI, Gregory J. RIGGINS, Theodore M. TARASOW
-
Patent number: 10220099Abstract: The synthesis of various pyrazino[1?,2?:1,5]pyrrolo[2,3-b]-indole-1,4-dione analogs has been successfully implemented in the present application. From these efforts, compounds having the structure of Formula I-c: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R4-R8, R3?, R6?, and n are as defined herein, are provided. These biologically active derivatives have been further used to prepare cell-specific drug conjugates effective in treating various diseases including cancer.Type: GrantFiled: May 10, 2016Date of Patent: March 5, 2019Assignees: Massachusetts Institute of Technology, The Board of Trustees of the University of IllinoisInventors: Mohammad Movassaghi, Justin Kim, Paul J. Hergenrother, Karen Morrison, Nicolas Boyer
-
Patent number: 10166229Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.Type: GrantFiled: December 20, 2016Date of Patent: January 1, 2019Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Karson S. Putt, Quinn P. Peterson, Valerie Fako
-
Publication number: 20180360824Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.Type: ApplicationFiled: July 17, 2018Publication date: December 20, 2018Applicant: The Board of Trustees of the University of IllinoisInventor: Paul J. HERGENROTHER
-
Publication number: 20180360830Abstract: The present invention, among other things, provides compounds, compositions and methods for treatment of cancer. In some embodiments, the present invention provides methods for treating blood cancer using agelastatin alkaloids.Type: ApplicationFiled: April 12, 2018Publication date: December 20, 2018Applicants: Massachusetts Institute of Technology, The Board of Trustees of the University of IllinoisInventors: Mohammad MOVASSAGHI, Paul J. HERGENROTHER
-
Patent number: 10085977Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: July 26, 2016Date of Patent: October 2, 2018Assignees: The Board of Trustees of the Univerity of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
-
Patent number: 10085978Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: August 22, 2016Date of Patent: October 2, 2018Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins UniversityInventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
-
Patent number: 10081592Abstract: The invention a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.Type: GrantFiled: March 25, 2013Date of Patent: September 25, 2018Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Robert W. Huigens, III, Karen C. Morrison, Robert W. Hicklin, II, Timothy A. Flood, Jr.